top of page
Companies in the News
Dec 21, 2022
DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions
The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...
Dec 19, 2022
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...
Dec 8, 2022
Federation Bio Administers First Dose in Phase 1 Clinical Trial
- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...
Nov 28, 2022
Escient Pharmaceuticals Announces $120 Million Series C Financing
Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and...
Nov 23, 2022
Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide
MEMPHIS, Tenn., Nov. 22, 2022 /PRNewswire/ -- Indigo Agriculture today announced the commercial launch of the industry's first biological...
Oct 11, 2022
Neumora Therapeutics Announces $112 Million Series B Financing
Proceeds to support the advancement of Neumora’s mission of building a leading global precision neuroscience company to revolutionize the...
Sep 14, 2022
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin
Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 Drug...
Aug 16, 2022
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE
Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells,...
May 31, 2022
Gritstone Announces Updated Overall Survival Results in CRC Patients from Phase 1/2 Study of GRANITE
Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy...
bottom of page